# Vernon K. Sondak

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vernon-k-sondak/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,194 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 88 |
| i10-index | 361 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5061209536 |
| ORCID iD | https://orcid.org/0000-0003-1090-484X |
| Works | 859 |

## Researcher papers

- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190](https://scholariq.org/papers/high-and-low-dose-interferon-alfa-2b-in-high-risk-melanoma-first-analysis-of/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials](https://scholariq.org/papers/meta-analysis-of-phase-ii-cooperative-group-trials-in-metastatic-stage-iv/)
- [Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma](https://scholariq.org/papers/phase-i-trial-of-interleukin-12-plasmid-electroporation-in-patients-with/)
- [PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression](https://scholariq.org/papers/pten-loss-confers-braf-inhibitor-resistance-to-melanoma-cells-through-the/)
- [Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases](https://scholariq.org/papers/multivariate-analysis-of-prognostic-factors-among-2-313-patients-with-stage-iii/)
- [Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy](https://scholariq.org/papers/recovery-of-phospho-erk-activity-allows-melanoma-cells-to-escape-from-braf/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)
- [Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma](https://scholariq.org/papers/clinicopathologic-predictors-of-sentinel-lymph-node-metastasis-in-thin-melanoma/)
- [Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)](https://scholariq.org/papers/metastasectomy-for-distant-metastatic-melanoma-analysis-of-data-from-the-first/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.